Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study

Table 3 Urinary symptoms improvement after switching from tolterodine ER to fesoterodine according to age of patients

Urinary symptoms (not at all = 0 to quite a lot = 5)	Total	<65 years	>65 years	P value between groups	r^₤
Worry
Frequency	3.2 (3.1-3.3)	3.2 (3.1-3.3)	3.3 (3.1-3.4)	0.325	0.056
Incontinence during sexual attempt	2.2 (2.2-2.3)	2.3 (2.2-2.4)	2.0 (1.9-2.2)	0.008	−0.128^‡
Nocturia	3.0 (2.9-3.1)	3.0 (2.9-3.1)	3.1 (3.0-3.3)	0.051	0.104^*
Frequency of infections	2.4 (2.3-2.5)	2.4 (2.2-2.5)	2.4 (2.2-2.5)	0.923	0.022
Urgency	3.2 (3.1-3.3)	3.2 (3.1-3.3)	3.3 (3.1-3.4)	0.585	0.044
Bladder pain	2.3 (2.3-2.4)	2.3 (2.2-2.4)	2.4(2.2-2.5)	0.775	0.034
Urge incontinence	3.1 (3.0-3.3)	3.1 (2.9-3.2)	3.2 (3.1-3.3)	0.211	0.055
Urinary difficulties	2.2 (2.1-2.3)	2.1 (2.0-2.2)	2.3 (2.2-2.4)	0.070	0.141^‡
Stress incontinence	2.2 (2.1-2.3)	2.1 (2.0-2.2)	2.2 (2.1-2.4)	0.266	0.028
Bother
Urinary frequency	3.2 (3.2-3.3)	3.2 (3.1-3.3)	3.3 (3.2-3.4)	0.453	0.029
Strong desire to urinate	3.3 (3.2-3.4)	3.3 (3.1-3.4)	3.3 (3.2-3.4)	0.642	0.022
Urine loss associated with a strong desire to urinate	3.1 (3.0-3.2)	3.1 (2.9-3.2)	3.2 (3.1-3.3)	0.117	0.055
Interference with daily-living activities
Usual activities	3.0 (2.9-3.1)	3.0 (2.9-3.1)	3.1 (2.9-3.2)	0.519	0.034
Leisure	3.1 (3.0-3.2)	3.1 (3.0-3.2)	3.1 (3.0-3.2)	0.761	−0.005
Work/domestic activities	2.5 (2.4-2.6)	2.7 (2.6-2.8)	2.2 (2.0-2.3)	<0.001	−0.197^‡

p significance level adjusted by sex, driven of treatment change, treatment adherence, treatment length, reason for switching; Values are mean (95% Confidence Interval) ^₤ Pearson coefficient of correlation between symptom score and age. *p < 0.05; ‡p ≤ 0.001.

ISSN: 1471-2490